{
  "id": 1,
  "text": "aire). The overall investment by all partners in NHa is \nover EUR 60 million, in equity and bond \nfinancing \n(guaranteed \nby \nthe \nNormandy \nRegion). IBAs contribution amounted to EUR 6 \nmillion in equity and EUR 1,5 million in \nconvertible Bond financing (see note 6.2.3). IBAs investment also includes the sale of \nintellectual property related to the Cyclone400 \ncyclotron to NHa. The gain on this transaction \namounted to EUR 5 million which was reduced \nby EUR 2 million (39.81%) for unrealized gain in \n2019. IBA has no capital commitments as at December \n31, 2022 and December 31, 2023 to participate \nin any potential future funding of Normandy \nHadrontherapy SAS.",
  "similarity_score": 0.7855030435577223,
  "metadata": {
    "filename": "annual_report_text (1).txt",
    "filepath": "input\\annual_report_text (1).txt",
    "chunk_id": 816,
    "start_char_idx": 0,
    "end_char_idx": 0,
    "page": null,
    "section": null
  }
}